Phil Skolnick Sells 4,321 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock

Share on StockTwits

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 4,321 shares of the firm’s stock in a transaction that occurred on Thursday, December 6th. The shares were sold at an average price of $16.06, for a total value of $69,395.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Phil Skolnick also recently made the following trade(s):

  • On Monday, November 5th, Phil Skolnick sold 1,821 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $18.01, for a total value of $32,796.21.
  • On Thursday, October 4th, Phil Skolnick sold 4,778 shares of Opiant Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total value of $87,532.96.

Shares of NASDAQ OPNT opened at $15.93 on Friday. The company has a market capitalization of $61.35 million, a price-to-earnings ratio of 38.10 and a beta of 0.24. Opiant Pharmaceuticals Inc has a 12 month low of $12.75 and a 12 month high of $32.28.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Wednesday, November 7th. The technology company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.21). The business had revenue of $4.37 million during the quarter, compared to the consensus estimate of $4.70 million. Opiant Pharmaceuticals had a negative return on equity of 175.03% and a negative net margin of 187.13%. On average, equities analysts anticipate that Opiant Pharmaceuticals Inc will post -4.59 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of OPNT. Northern Trust Corp acquired a new stake in shares of Opiant Pharmaceuticals during the second quarter valued at about $350,000. Brasada Capital Management LP acquired a new stake in shares of Opiant Pharmaceuticals during the third quarter valued at about $268,000. Granite Point Capital Management L.P. acquired a new stake in shares of Opiant Pharmaceuticals during the third quarter valued at about $1,340,000. Stonepine Capital Management LLC purchased a new position in shares of Opiant Pharmaceuticals in the third quarter valued at approximately $3,320,000. Finally, Vanguard Group Inc. boosted its stake in shares of Opiant Pharmaceuticals by 25.1% in the third quarter. Vanguard Group Inc. now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after purchasing an additional 21,151 shares during the period. 17.01% of the stock is currently owned by institutional investors.

Several brokerages have commented on OPNT. Cantor Fitzgerald set a $42.00 price target on Opiant Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 28th. ValuEngine raised Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 4th.

TRADEMARK VIOLATION WARNING: “Phil Skolnick Sells 4,321 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock” was originally reported by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/12/08/phil-skolnick-sells-4321-shares-of-opiant-pharmaceuticals-inc-opnt-stock/3064270.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Article: What are the benefits of a balanced fund?

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.